Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Evaluation Of Brentuximab Vedotin For Diffuse Cutaneous Systemic Sclerosis (BRAVOS)

Principal Investigator

David Fox, MD | University of Michigan | Ann Arbor, MI
Dinesh Khanna, MD | University of Michigan | Ann Arbor, MI

Locations

Georgetown University | Washington, DC
University of Michigan | Ann Arbor, MI
Hospital for Special Surgery | New York, NY
University of California Los Angeles | Los Angeles, CA
Boston University | Boston, MA
University of Pittsburgh | Pittsburgh, PA
Medical University of South Carolina | Charleston, SC
University of Texas | Houston, TX
Duke University | Durham, NC

Study Code

ITN075AI

Study Status

Active

Abstract

The main goal of the BRAVOS study is to determine the safety of an investigational study drug, brentuximab vedotin (ADCETRIS®), in diffuse cutaneous systemic sclerosis (dcSSc). Researchers will also assess whether ADCETRIS® has any effect on symptoms associated with dcSSc, and will examine the effect of the ADCETRIS® on the immune system by looking at blood and skin samples.   

BRAVOS is a placebo-controlled trial, double-blinded study. Three quarters of participants will receive one of three dosages of brentuximab vedotin (ADCETRIS®) and one quarter will receive placebo. 

A total of eight doses of brentuximab vedotin (ADCETRIS®) or placebo will be given by intravenous infusion once every 3 weeks over a 21 week period. Then there will be 4 follow-up visits over the next 6 months. Total study time is 1 year.

Brentuximab vedotin (ADCETRIS®) is approved by the FDA for the treatment of Hodgkin’s and other lymphomas. Researchers think brentuximab vedotin (ADCETRIS®) might also work in dcSSc by attaching to the immune cells that cause dcSSc. Since it has never been tested in patients with dcSSC, brentuximab vedotin (ADCETRIS®) it is considered an experimental drug for this disease.

Brentuximab vedotin (ADCETRIS®) attaches to the CD30 protein on cells and releases a toxin into the cell, causing the cell to die. CD30 is a protein found at low levels on the surface of normal healthy white blood cells. However, the CD30 protein is increased on certain types of cancer cells, and also may be increased on the overactive immune cells involved with inflammation and fibrosis in dcSSc.  

About This Study

The main goal of the BRAVOS study is to determine the safety of an investigational study drug, brentuximab vedotin (ADCETRIS®), in diffuse cutaneous systemic sclerosis (dcSSc). Researchers will also assess whether ADCETRIS® has any effect on symptoms associated with dcSSc, and will examine the effect of the ADCETRIS® on the immune system by looking at blood and skin samples.   

Participating in BRAVOS

BRAVOS is a placebo-controlled trial, which means that some participants will get brentuximab vedotin (ADCETRIS®) and some will get an inactive substance called a placebo. This study is double-blinded, which means that during the study neither you nor your study doctor will know whether you are receiving brentuximab vedotin (ADCETRIS®) or placebo. Three quarters of participants will receive one of three dosages of brentuximab vedotin (ADCETRIS®) and one quarter will receive placebo. You cannot choose your group. A computer randomly picks who gets brentuximab vedotin (ADCETRIS®) and who gets placebo. 

A total of eight doses of brentuximab vedotin (ADCETRIS®) or placebo will be given by intravenous infusion once every 3 weeks over a 21 week period. Then there will be 4 follow-up visits over the next 6 months. Total study time is 1 year.

About the Investigational Study Drug

Brentuximab vedotin (ADCETRIS®) is approved by the FDA for the treatment of Hodgkin’s and other lymphomas. Researchers think brentuximab vedotin (ADCETRIS®) might also work in dcSSc by attaching to the immune cells that cause dcSSc. Since it has never been tested in patients with dcSSC, brentuximab vedotin (ADCETRIS®) it is considered an experimental drug for this disease.

Brentuximab vedotin (ADCETRIS®) attaches to the CD30 protein on cells and releases a toxin into the cell, causing the cell to die. CD30 is a protein found at low levels on the surface of normal healthy white blood cells. However, the CD30 protein is increased on certain types of cancer cells, and also may be increased on the overactive immune cells involved with inflammation and fibrosis in dcSSc.  

[Clinicaltrials.gov] [Study Website]

Do you Qualify for this Clinical Trial?

To learn more about this study and whether you are eligible to participate, please visit the study website: Bravos-Study.org.

Principal Investigator

David Fox, MD | University of Michigan | Ann Arbor, MI
Dinesh Khanna, MD | University of Michigan | Ann Arbor, MI

Locations

Georgetown University | Washington, DC
University of Michigan | Ann Arbor, MI
Hospital for Special Surgery | New York, NY
University of California Los Angeles | Los Angeles, CA
Boston University | Boston, MA
University of Pittsburgh | Pittsburgh, PA
Medical University of South Carolina | Charleston, SC
University of Texas | Houston, TX
Duke University | Durham, NC

Contact a study site near you.

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility